Stuttgart
22.10.26 | 08:39
3,020 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.10. | Inventiva S.A. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 06.10. | INVENTIVA: Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting 2026 | 549 | GlobeNewswire (Europe) | Preclinical data showed that balanced PPARa, PPARd and PPAR? activation by lanifibranor affects complementary pathways across multiple hepatic cell populations involved in fibrosis in MASH pathogenesisPreclinical... ► Artikel lesen | |
| 04.10. | Inventiva (IVA): How Much Is One Make-or-Break Readout Really Worth? | 11 | Insider Monkey | ||
| 30.09. | Inventiva Ends First Half With €233.9 Million In Cash And Deposits Ahead Of Phase 3 NATiV3 Results | 11 | pulse2.com | ||
| INVENTIVA SA ADR Aktie jetzt für 0€ handeln | |||||
| 30.09. | Inventiva auf Stifel-Forum für Kardiometabolik: Lanifibranor vor entscheidendem Test | 14 | Investing.com Deutsch | ||
| 28.09. | Truist bestätigt Kaufempfehlung für Inventiva Aktie vor Phase-3-Daten | 19 | Investing.com Deutsch | ||
| 28.09. | Truist reiterates Buy on Inventiva stock ahead of phase 3 data | 5 | Investing.com | ||
| 28.09. | Inventiva H1 2026 Earnings Call: Complete Transcript | 2 | Benzinga.com | ||
| 28.09. | Inventiva S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 28.09. | Inventiva S.A reports 1H results | 6 | Seeking Alpha | ||
| 28.09. | Inventiva H1 Loss Drops | 12 | RTTNews | ||
| 28.09. | INVENTIVA: Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update | 744 | GlobeNewswire (Europe) | Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits1 as of June 30, 2026Cash runway guidance remains unchanged from July 30, 20262Topline results of the Phase 3 NATiV3... ► Artikel lesen | |
| 23.09. | Stifel reiterates Buy on Inventiva stock, $15 target on MASH drug | 17 | Investing.com | ||
| 18.09. | Stifel reiterates Buy on Inventiva stock ahead of trial data | 11 | Investing.com | ||
| 15.09. | Guggenheim raises Inventiva stock price target on trial outlook | 11 | Investing.com | ||
| 08.09. | INVENTIVA: Inventiva to Present Multiple Abstracts at Paris MASH 2026 | 823 | GlobeNewswire (Europe) | Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic profile and cardiovascular risk factors in patients with MASH with or without type 2 diabetesPreclinical data further characterize... ► Artikel lesen | |
| 03.09. | Inventiva appoints Chris Benecchi as Chief Operating Officer | 14 | PMLiVE | ||
| 03.09. | Inventiva S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.09. | INVENTIVA: Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH | 1.232 | GlobeNewswire (Europe) | Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohortTopline results of NATiV3 expected in Q4 2026September... ► Artikel lesen | |
| 31.08. | INVENTIVA: Inventiva Appoints Chris Benecchi as Chief Operating Officer | 745 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), August 31, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen |
1 2 3 Weiter >>
59 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EYEPOINT | 0,380 | -1,04 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 78,42 | -0,33 % | FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death | ||
| HAPPY BELLY FOOD GROUP | 0,930 | +2,76 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Heal Wellness QSR Announces the Grand Opening of Its 54th Location in Calgary's Crowfoot Village | Toronto, Ontario--(Newsfile Corp. - October 16, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 191,20 | +1,35 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026 | Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
DUBLIN, Oct. 19, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its... ► Artikel lesen | |
| DAIICHI SANKYO | 15,932 | -0,60 % | Pink October: Daiichi Sankyo unterstützt neue Podcast-Reihe von Pink Ribbon Deutschland zur Brustkrebsaufklärung | München/Pfaffenhofen (ots) - Eine Brustkrebsdiagnose stellt das Leben auf den Kopf. Neben medizinischen Fragen verändern sich auch Alltag, Beziehungen, Zukunftspläne und das eigene Selbstbild. Themen... ► Artikel lesen | |
| AYTU BIOPHARMA | 1,900 | -100,00 % | Aytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results | Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarterFourth quarter fiscal 2026 Adjusted EBITDA of $0.5 millionEXXUA net revenue of $6.6... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 42,300 | 0,00 % | Rigel Pharmaceuticals, Inc.: Rigel Reports Second Quarter 2026 Financial Results | Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations of $11.7 million, and... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 2,280 | -2,77 % | NRx Pharmaceuticals completes manufacturing validation for preservative-free ketamine | ||
| TUHURA BIOSCIENCES | 1,910 | +2,69 % | TuHURA Biosciences, Inc./NV - 8-K, Current Report | ||
| CGN MINING | 0,218 | -8,40 % | HSBC Research Initiates Coverage on CGN MINING with Buy Rating, TP at HKD3 | ||
| CHINA SHINEWAY PHARMACEUTICAL GROUP | 0,850 | +1,19 % | Dividendenbekanntmachungen (15.10.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,63 USD 0,5648 EUR ABBOTT LABORATORIES CDR CA0028221046 0,1096 CAD 0,069 EUR ABBVIE INC US00287Y1091 1... ► Artikel lesen | |
| FUTURA MEDICAL | 0,001 | 0,00 % | Futura Medical PLC - Board Change and Formal Sale Process Update | ||
| BAYER | 44,630 | +2,64 % | Bayer nach 15 % Kursverlust Stabilisierung an der 200-Tage-Linie | Nach dem Rückgang von mehr als 15 % hat sich die Bayer-Aktie im Bereich der 200-Tage-Linie stabilisiert. Gleichzeitig bleibt der Bruch der früheren Unterstützung und die weiterhin neutrale Korrekturphase... ► Artikel lesen | |
| MERCK KGAA | 142,25 | -2,83 % | ROUNDUP/Aktien New York Schluss: Nasdaq etwas erholt - Dow fast unverändert | NEW YORK (dpa-AFX) - Nach der jüngsten Talfahrt hat die technologielastige US-Börse Nasdaq am Montag einen Erholungsversuch gestartet. Der Nasdaq-Auswahlindex 100 legte um 1,17 Prozent auf 29.529,34... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 40,590 | -0,06 % | Teva/Sanofi: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension... ► Artikel lesen |
Das Unternehmen INVENTIVA SA ADR kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 3,020 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INVENTIVA SA ADR finden Sie auf Wallstreet Online.